Endostar Combined with Cisplatin Inhibits Tumor Growth and Lymphatic Metastasis of Lewis Lung Carcinoma Xenografts in Mice

Objective: To investigate the effects of endostar, a recombined humanized endostatin, plus cisplatin on thegrowth, lymphangiogenesis and lymphatic metastasis of the Lewis lung carcinoma (LLC) in mice.
Methods: Atumor model were established in C57BL/6 mice by intravenious transplantation of LLC cells. Then the mice wererandomized to receive administration with NS, endostar, cisplatin, or endostar plus cisplatin. After the mice weresacrificed, tumor multiplicity, tumor size and lymph node metastasis were assessed. Then the expression of vascularendothelial growth factor-c (VEGF-C) and podoplanin were determined by immunohistochemical staining.
Results: Endostar plus cisplatin significantly suppressed tumor growth. lymphatic metastasis and prolongedsurvival time of the mice without obvious toxicity. The inhibition of lymphatic metastasis was associated withdecreased microlymphatic vessel density (MLVD) and expression of VEGF-C.
Conclusions: Endostar combinedwith cisplatin was more effective to suppress tumor growth and lymphatic metastasis than either agent alone.Thus this may provide a rational alternative for lung carcinoma treatment.